Diabetes as a pan-cancer risk factor: Triangulated evidence from global burden, longitudinal cohorts, and Mendelian randomization
World Journal of Diabetes · 2026-11-15 · 17 (11)
DOI: 10.4239/wjd.124123 ↗Abstract
BACKGROUND Diabetes has been implicated in cancer initiation and progression; however, its contribution to cancer burden, risk, and survival remains insufficiently defined across populations, geographical regions, and analytical frameworks. AIM To systematically evaluate the impact of diabetes on pan-cancer and delineate shared risk patterns across malignancies. METHODS We integrated the Global Burden of Disease, National Health and Nutrition Examination Survey (NHANES), the National Death Index mortality data, China Health and Retirement Longitudinal Study, and genome-wide association study datasets. The Global Burden of Disease estimates were used to assess temporal trends. Multivariable logistic regression was used to examine associations between diabetes and cancer prevalence; Kaplan-Meier, Cox proportional hazards, and competing risk analyses were used to evaluate survival outcomes; and Mendelian randomization was used to assess genetic evidence for causality. RESULTS The cancer burden attributable to high fasting plasma glucose levels increased steadily from 1990 to 2021. After multivariable adjustment, diabetes was independently associated with higher cancer prevalence in NHANES (odds ratio = 1.64, 95%CI: 1.18-2.28) and China Health and Retirement Longitudinal Study cohort (odds ratio = 2.00, 95%CI: 1.11-3.59), and with poorer survival (hazard ratio = 1.25, 95%CI: 1.03-1.51) in NHANES. Participants with diabetes generally exhibit higher cancer-specific mortality rates. Mendelian randomization further supported a causal association between diabetes and overall cancer risk, while established diabetes-related markers showed dose-response associations with cancer prevalence. CONCLUSION These findings identify diabetes as a systemic pan-cancer risk factor associated with increase cancer burden, elevated cancer risk, and poor survival outcomes.
EUVIMED